Merit E Cudkowicz Selected Research

CK-2017357

1/2019	A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.
1/2018	VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
9/2012	Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Merit E Cudkowicz Research Topics

Disease

47	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2022 - 07/2003
10	Disease Progression 01/2022 - 05/2007
5	Atrophy 10/2021 - 03/2006
5	Huntington Disease (Huntington's Disease) 01/2017 - 03/2006
3	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 08/2003
3	Dizziness (Lightheadedness) 01/2019 - 09/2012
3	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 09/2018 - 01/2016
3	Parkinson Disease (Parkinson's Disease) 02/2014 - 06/2007
2	Neuroinflammatory Diseases 01/2022 - 05/2007
2	Fatigue 01/2019 - 09/2012
2	Muscle Cramp (Cramp) 03/2018 - 04/2016
2	Multiple Sclerosis 01/2018 - 01/2016
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2015 - 05/2007
2	Nervous System Diseases (Neurological Disorders) 05/2013 - 11/2011
2	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2009 - 05/2007
2	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2008 - 06/2007
1	Diarrhea 10/2022
1	Paresthesia (Dysesthesia) 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2022
1	Ischemic Optic Neuropathy (Anterior Ischemic Optic Neuropathy) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Myasthenia Gravis 12/2021
1	Nausea 01/2019
1	Weight Loss (Weight Reduction) 01/2019
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2019
1	Chronic Progressive Multiple Sclerosis 01/2018
1	Headache (Headaches) 01/2018
1	Rare Diseases (Rare Disease) 12/2017
1	Inflammation (Inflammations) 01/2015
1	Sarcoma (Soft Tissue Sarcoma) 04/2014
1	Gout 02/2014
1	Urolithiasis 02/2014
1	Neutropenia 11/2013
1	Muscular Dystrophies (Muscular Dystrophy) 05/2013
1	Cognitive Dysfunction 09/2012
1	Multiple System Atrophy 09/2012
1	Body Weight (Weight, Body) 04/2009
1	Gliosis 04/2009
1	Osteoporosis 01/2009
1	Metabolic Bone Diseases (Osteopenia) 01/2009
1	Muscle Weakness 01/2009
1	Pain (Aches) 01/2009

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2005
5	4-phenylbutyric acid (Buphenyl)FDA Link 01/2021 - 06/2005
4	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2015 - 01/2013
3	Biological ProductsIBA 01/2022 - 02/2014
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2007
3	Pharmaceutical PreparationsIBA 01/2022 - 05/2013
3	Mexiletine (Mexitil)FDA LinkGeneric 01/2021 - 04/2016
3	ibudilastIBA 01/2021 - 01/2016
3	TroponinIBA 01/2019 - 09/2012
3	CK-2017357IBA 01/2019 - 09/2012
3	DexpramipexoleIBA 09/2014 - 01/2013
3	coenzyme Q10 (CoQ10)IBA 09/2010 - 03/2006
2	Nerve Growth Factors (Neurotrophins)IBA 01/2022 - 12/2019
2	ursodoxicoltaurineIBA 01/2021 - 01/2020
2	Superoxide Dismutase-1IBA 01/2020 - 04/2014
2	Retinaldehyde (Retinal)IBA 01/2018 - 01/2016
2	Glutamic Acid (Glutamate)FDA Link 01/2015 - 11/2014
2	Uric Acid (Urate)IBA 02/2014 - 09/2012
1	RT001IBA 10/2022
1	lipid peroxidation inhibitorIBA 10/2022
1	JNK Mitogen-Activated Protein KinasesIBA 01/2022
1	Dynamins (Dynamin)IBA 01/2022
1	GTP Phosphohydrolases (GTPases)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Rituximab (Mabthera)FDA Link 12/2021
1	Cholinergic ReceptorsIBA 12/2021
1	4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA 10/2021
1	ezogabine (retigabine)IBA 01/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2020
1	CreatineIBA 01/2020
1	Tamoxifen FDA LinkGeneric 01/2020
1	Cromolyn Sodium (Cromoglicic Acid)FDA LinkGeneric 11/2019
1	Neuroprotective AgentsIBA 11/2019
1	Indicators and Reagents (Reagents)IBA 07/2018
1	Toll-Like Receptor 4IBA 01/2018
1	Macrophage Migration-Inhibitory FactorsIBA 01/2018
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2018
1	Cyclic NucleotidesIBA 01/2018
1	Cephalosporins (Cephalosporin Antibiotics)IBA 10/2014
1	CreatinineIBA 09/2014
1	Inosine FDA Link 02/2014
1	Messenger RNA (mRNA)IBA 05/2013
1	Antisense OligonucleotidesIBA 05/2013
1	Immunoglobulin G (IgG)IBA 11/2011
1	Immunoglobulin M (IgM)IBA 11/2011
1	AntigensIBA 11/2011
1	AntibodiesIBA 11/2011
1	Superoxide DismutaseIBA 11/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2011
1	Histone Deacetylase InhibitorsIBA 04/2009
1	Riluzole FDA LinkGeneric 04/2009
1	Risedronic Acid (Actonel)FDA LinkGeneric 01/2009
1	Diphosphonates (Bisphosphonates)IBA 01/2009

Therapy/Procedure

11	Therapeutics 01/2022 - 03/2006
2	Noninvasive Ventilation 01/2022 - 07/2011
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022
1	Drug Tapering 01/2022